Discover how autonomic biomarkers like HRV and baroreflex sensitivity offer critical insights into cardiovascular risk that traditional metrics often overlook.
Published October 29, 2026 · Updated November 5, 2026
Traditional cardiovascular risk assessment remains heavily reliant on established parameters such as blood pressure, lipid panels, and glycemic control. While these metrics are foundational, they frequently fail to capture the complex physiological degradation often preceding acute cardiac events. The emergence of autonomic biomarkers has shifted the diagnostic paradigm, allowing clinicians to quantify the neurocardiac integrity that dictates long-term patient outcomes.
The autonomic nervous system (ANS) serves as the primary mediator of cardiovascular homeostasis. Dysregulation—manifesting as reduced vagal tone or sympathetic overactivity—is not merely a symptom of pathology; it is an active driver of disease progression. Cardiac autonomic testing has revealed that reduced Heart Rate Variability (HRV) is an independent predictor of sudden cardiac death and heart failure progression. By utilizing an HRV biomarker, physicians can identify patients at high risk even when standard echocardiography or stress testing shows nominal results. Baroreflex sensitivity, similarly, serves as a dynamic measure of the system's ability to buffer blood pressure fluctuations, providing a window into systemic vascular resilience.
Transitioning from theory to office-based practice requires instrumentation that is both precise and workflow-efficient. The VitalScan ANS+ system by US MedResources is designed for seamless clinical integration. It offers a comprehensive, 15-minute non-invasive test that can be administered by existing staff without requiring a specialized technician. The platform generates an automated, interpretive report while the patient is still in the exam room, facilitating immediate clinical decision-making.
The system evaluates a comprehensive suite of indices: Heart Rate Variability, Valsalva ratio, orthostatic blood pressure response, sudomotor function via SudoCheck, Pulse Wave Velocity (PWV), and Ankle-Brachial Index (ABI). This multidimensional data allows for robust autonomic risk stratification, providing physicians with a 360-degree view of the patient’s hemodynamic and autonomic stability.
For cardiology practices, the integration of objective autonomic data is supported by clear reimbursement pathways. Testing procedures performed with the VitalScan ANS+ system fall under established CPT billing codes, including 95921-95924 for autonomic nervous system testing and 93922-93971 for comprehensive vascular studies. These codes allow practices to maintain financial sustainability while enhancing the standard of care provided to patients with complex comorbidities.
Clinical guidelines from organizations such as the AHA and ACC emphasize the importance of identifying subclinical markers of vascular aging and autonomic dysfunction. By adopting this technology, cardiology practices can align with these gold-standard recommendations, moving beyond traditional symptomatic management toward true physiologic prevention.
Autonomic biomarkers provide an indispensable layer of prognostic data that extends beyond traditional cardiovascular risk factors. By incorporating the VitalScan ANS+ system into your cardiology workflow, you can leverage advanced diagnostics—including HRV, PWV, and ABI—to enhance patient outcomes and improve risk stratification, all supported by efficient, office-based implementation and clear CPT billing protocols.
One-Page Reference
Code descriptions, typical reimbursement ranges, ICD-10 pairings, and the CMS bundling note to check before you bill.
Combine cardiac autonomic testing with your vascular studies at your own volume and reimbursement, and see the annual figure.